The Age-Related Macular Degeneration (AMD) Market is poised for significant growth over the next decade. According to the latest analysis by Renub Research, the global AMD market is estimated to reach US$ 20.88 billion by 2033, rising from US$ 11.42 billion in 2024, with a CAGR of 6.94% between 2025 and 2033. This growth is driven by an aging global population, increasing awareness about retinal diseases, and the introduction of advanced diagnostic tools and innovative therapies.
AMD, a progressive eye condition that primarily affects individuals over 50, is a leading cause of vision loss. With modern lifestyles contributing to risk factors such as smoking, obesity, and hypertension, the prevalence of AMD is steadily increasing worldwide. These factors are further amplified by longer life expectancies, creating a robust demand for early detection and effective treatment options.
For a detailed market report, visit: Age-Related Macular Degeneration Market Report.
Growing Prevalence of Age-Related Macular Degeneration
Globally, the number of people aged 60 and above is rising rapidly, and with it, the prevalence of AMD is also increasing. As per industry studies, millions of individuals suffer from some form of AMD, with wet AMD (neovascular AMD) being the leading cause of severe vision impairment. The demand for anti-VEGF (vascular endothelial growth factor) drugs, laser therapies, and new biologics is expected to grow steadily in the coming years.
Moreover, awareness campaigns by healthcare organizations and non-profits are encouraging regular eye screenings, enabling early-stage detection and intervention. Early detection is crucial in slowing disease progression and reducing the burden on healthcare systems.
Key Market Drivers
1. Aging Population
The global population of people aged 65 and above is projected to nearly double by 2050, significantly increasing the pool of individuals at risk of AMD. This demographic shift will be a primary driver of market growth.
2. Innovative Treatments and Therapies
Pharmaceutical companies are investing heavily in developing new drugs and advanced biologics that offer better outcomes for AMD patients. Gene therapies and regenerative medicine are emerging as promising frontiers in the treatment of retinal disorders.
3. Improved Diagnostic Tools
Advancements in imaging technologies, such as Optical Coherence Tomography (OCT) and fundus autofluorescence imaging, are enabling earlier and more accurate detection of AMD.
4. Rising Awareness and Screening Programs
Public health campaigns and government initiatives are increasing awareness about eye health, especially in developed nations. Routine eye checkups and improved access to healthcare services are supporting early interventions.
5. Lifestyle-Related Risk Factors
Changing lifestyles, including increased screen time, poor dietary habits, and smoking, are contributing to the growing number of AMD cases globally.
Market Segmentation
By Disease Type:
-
Dry AMD: Accounts for a larger patient pool but progresses slowly, creating demand for long-term care.
-
Wet AMD: Though less common, wet AMD requires intensive treatment and contributes a significant share of market revenue due to expensive therapies.
By Drug Class:
-
Anti-VEGF Injections (e.g., Ranibizumab, Aflibercept, Brolucizumab)
-
Corticosteroids
-
Photodynamic Therapy Drugs
-
Emerging Gene Therapies and Stem Cell-Based Treatments
By End-User:
-
Hospitals
-
Ophthalmic Clinics
-
Ambulatory Surgery Centers
-
Research and Academic Institutes
Competitive Landscape
The AMD market is characterized by the presence of major pharmaceutical and biotechnology companies striving to expand their portfolios with innovative solutions. Some of the key players in the market include:
-
Roche Holding AG
-
Novartis AG
-
Regeneron Pharmaceuticals
-
Bayer AG
-
Pfizer Inc.
-
Biogen Inc.
Strategic collaborations, mergers, and acquisitions are common in the sector, as companies aim to leverage advanced technologies and expand their global reach.
Regional Insights
North America
North America dominates the global AMD market due to its advanced healthcare infrastructure, high awareness levels, and early adoption of innovative therapies. The U.S. is a major hub for AMD drug development and clinical trials.
Europe
Europe is witnessing substantial growth, driven by strong government healthcare policies, aging demographics, and widespread availability of advanced diagnostic tools. Countries like Germany, the UK, and France are leading markets in this region.
Asia-Pacific
Asia-Pacific is expected to register the fastest CAGR during 2025–2033, thanks to its rapidly aging population, improving healthcare infrastructure, and rising healthcare expenditure in countries like Japan, China, and India.
Rest of the World
Regions such as Latin America and the Middle East are showing steady growth, driven by increasing awareness of eye health and improving access to advanced treatments.
Future Outlook of the AMD Market
The AMD market is on the cusp of transformative changes. Innovations such as sustained-release drug delivery systems, long-acting anti-VEGF agents, and regenerative medicine are expected to enhance patient outcomes significantly. Moreover, the integration of artificial intelligence (AI) in diagnostics will enable personalized treatment plans and better disease monitoring.
10 FAQs on the Age-Related Macular Degeneration Market
1. What is the current size of the AMD market?
The AMD market was valued at US$ 11.42 billion in 2024.
2. What is the forecasted market size by 2033?
It is projected to reach US$ 20.88 billion by 2033 at a CAGR of 6.94%.
3. What are the main types of AMD?
There are two main types: Dry AMD and Wet AMD.
4. Which type of AMD contributes the most to market revenue?
Wet AMD contributes a larger share of revenue due to the higher cost of therapies.
5. What are anti-VEGF therapies?
Anti-VEGF (vascular endothelial growth factor) therapies are injections that reduce abnormal blood vessel growth and leakage in the retina, a hallmark of wet AMD.
6. Which region dominates the AMD market?
North America leads the market due to its advanced healthcare system and significant research investments.
7. What are the key factors driving AMD market growth?
Aging populations, improved diagnostic tools, lifestyle-related risk factors, and novel treatment options are key drivers.
8. Are there any new therapies on the horizon?
Yes, emerging gene therapies, long-acting anti-VEGF drugs, and stem cell treatments are expected to reshape the market.
9. How is AI impacting AMD diagnostics?
AI is being integrated into diagnostic imaging to detect early signs of AMD with higher accuracy and speed.
10. Which companies are leading the AMD market?
Key players include Roche, Novartis, Regeneron, Bayer, Pfizer, and Biogen
New Publish Report:
- China Organic Dairy Market Size and Share Analysis – Growth Trends and Forecast Report 2025-2033
- China Organic Baby Food Market Size and Share Analysis – Growth Trends and Forecast Report 2025-2033
- China Microwave Oven Market Size and Share Analysis – Growth Trends and Forecast Report 2025-2033
.
About the Company – Renub Research
Renub Research is a Market Research and Consulting Company with more than 15 years of experience, especially in international Business-to-Business Research, Surveys, and Consulting. We provide a wide range of business research solutions that help companies make better business decisions. We partner with clients across all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
Our wide clientele includes key players in Healthcare, Travel & Tourism, Food & Beverages, Power & Energy, Information Technology, Telecom & Internet, Chemicals, Logistics & Automotive, Consumer Goods & Retail, Building & Construction, and Agriculture. Our core team comprises experienced professionals with graduate, postgraduate, and Ph.D. qualifications in Finance, Marketing, Human Resources, Bio-Technology, Medicine, Information Technology, Environmental Science, and more.
Media Contact:
Company Name: Renub Research
Contact Person: Rajat Gupta, Marketing Manager
Phone No: +91-120-421-9822 (IND) | +1-478-202-3244 (USA)
Email: rajat@renub.com